Evaluation of the quality of life and satisfaction with the therapy in patients with type 1 diabetes — is Medtronic MiniMed 640G system able to improve it? Preliminary insights

Tabor, Aleksandra; Gawel, Wladyslaw; Goik, Oliwia; Deja, Marek; Jarosz-Chobot, Przemysława

doi:10.5603/dk.2017.0002

Cited by 6 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Slightly more than 50% of the respondents reported that a child was more willing to integrate with peers, was calmer, and was more engaged in the process of self-monitoring. These results are confirmed by the literature data, where as many as 46% of the respondents noticed greater involvement of children in disease control after using the 640G pumpintegrated CGM system, although the children were older (average age 8 years) [24].…”

Section: Discussionsupporting

confidence: 86%

“…An undeniable benefit, however, remains the significant reduction in the fingerstick glycemia measurements, confirmed by a previous study in our children's clinic, where the number of fingerstick glycemia measurements was reduced on average by 50% (from 12 to 3 measurements per day at most) [24]. In addition, the current analysis revealed a very high sense of security when using a CGM system compared to the era without CGM.…”

Section: Discussionsupporting

confidence: 84%

“…Hypoglycemia is one of the most frequent acute complications of insulin therapy which arouses anxiety. Severe hypoglycemia occurs in about 5–12% of children and is a serious problem [ 23 , 24 ]. It is the main indication for the use of CGM in the youngest children, which protects against an unexpected drop in blood glucose concentration.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

The Quality of Life and Satisfaction with Continuous Glucose Monitoring Therapy in Children under 7 Years of Age with T1D Using the rtCGM System Integrated with Insulin Pump—A Caregivers Point of View

Rusak

Ogarek

Wolicka

et al. 2021

Sensors

Self Cite

View full text Add to dashboard Cite

Quality of life (QoL) is an important parameter that affects the choice of therapy. Assessment of QoL and satisfaction with therapy using the rtCGM in children with T1D aged < 7 years was conducted. The study group consisted of 38 children with T1D aged < 7 years (34% aged 2–4, 66% aged 5–7 years), HbA1c: 6.53 ± 0.63%, duration of diabetes: 2.6 ± 1.6 years, treated with an rtCGM-augmented insulin pump for 1.92 ± 1.15 years. Two anonymous surveys were conducted: a. PedsQL3.0 diabetes standardized questionnaire—QoL assessment among age groups: 2–4/5–7 years. b. An original survey assessing the CGM use satisfaction. The mean scores in PedsQL3.0: communication 75%, worries 30%, treatment 70%, and problems associated with diabetes 65%. The QoL scale is: 0–19% very low, 20–39% low, 40–59% moderate, 60–79% high, 80–100% very high. The most frequently reported concerns were long-term diabetes complications and prick pain. Satisfaction with CGM use was high (68% in group aged 5–7 and 92% 2–4 years). Twenty-seven (71%) caregivers confirmed the positive effect of CGM on sleep. During the use of rtCGM a high quality of life was reported, and the quality of sleep in their caregivers was increased.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Quality of Life and Satisfaction with Continuous Glucose Monitoring Therapy in Children under 7 Years of Age with T1D Using the rtCGM System Integrated with Insulin Pump—A Caregivers Point of View

Rusak

Ogarek

Wolicka

et al. 2021

Sensors

Self Cite

View full text Add to dashboard Cite

show abstract

“…These findings are extremely important for caregivers, since young children frequently do not report hypoglycemia to caregivers. The responsibility of managing blood glucose levels rests with caregivers, which distinctly deteriorates their quality of life . Following the state of constant anxiety and deprivation of sleep due to the need to take care of their child is worsening the child's glycemic control in the long run .…”

Section: Discussionmentioning

confidence: 99%

How does a predictive low glucose suspend (PLGS) system tackle pediatric lifespan challenges in diabetes treatment? Real world data analysis

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objectives: The aim of the study was to assess the benefits of a predictive low glucose suspend (PLGS) system in real-life in children and adolescents with type 1 diabetes of different age and age-related clinical challenges.Methods: Real life retrospective and descriptive analysis included 44 children (26 girls) with type 1 diabetes who were introduced to PLGS system. We divided them in three age groups: I (3-6 years old, n = 12), II (7-10 y/o, n = 16), III (11-19 y/o, n = 16). All children and their caregivers received unified training in self-management during PLGS therapy. Patients' data included: age, HbA1C levels, sex. While from the CGM metric, we obtained: time of sensor use (SENSuse), time in range (TiR): in, below and over target range and average blood glycemia (AVG), insulin suspension time (INSsusp).Results: SENSuse was 93% in total, with 92%, 94%, and 87% in age groups I, II, III, respectively. In total the reduction of mean HbA1C from 7.61% to 6.88% (P < .05), while for the I, II, and III it was 7.46% to 6.72%, 6.91% to 6.41%, and 8.46 to 7.44%, respectively (P < .05). Although we observed a significant reduction of HbA1C, the time below target range was minimal. Specific findings included: group I-longest INSsusp (17%), group II-lowest glycemic variability (CV) (36%), and group III-highest AVG (169 mg/dL). There was a reverse correlation between suspend before low and age (−0.32, P < .05). In group I CV reduced TiR in target range (TiRin) (−0.82, P < .05), in group II use of complex boluses increased TiRin (0.52, P < .05). In group III higher CV increased HbA1C (0.64, P < .05) while reducing TiRin (−0.72, P < .05).Conclusions: PLGS is a suitable and safe therapeutic option for children with diabetes of all age and it is effective in addressing age-specific challenges. PLGS improves glycemic control in children of all age, positively affecting its different parameters. K E Y W O R D Sdiabetes, insulin pumps, technology

show abstract

“…This integrated system has shown efficacy in reducing hypoglycemia 2 and improving quality of life. 3 Even so, many users fail to achieve their target glucose levels.…”

Section: Dear Editormentioning

confidence: 99%

The Effect of Frequency of Technology Uploads on Glycemic Control in Adult Insulin Pump Users

Gannon

O’Keeffe

O'Sullivan

2020

J Diabetes Sci Technol

View full text Add to dashboard Cite

Evaluation of the quality of life and satisfaction with the therapy in patients with type 1 diabetes — is Medtronic MiniMed 640G system able to improve it? Preliminary insights

Cited by 6 publications

References 15 publications

The Quality of Life and Satisfaction with Continuous Glucose Monitoring Therapy in Children under 7 Years of Age with T1D Using the rtCGM System Integrated with Insulin Pump—A Caregivers Point of View

The Quality of Life and Satisfaction with Continuous Glucose Monitoring Therapy in Children under 7 Years of Age with T1D Using the rtCGM System Integrated with Insulin Pump—A Caregivers Point of View

How does a predictive low glucose suspend (PLGS) system tackle pediatric lifespan challenges in diabetes treatment? Real world data analysis

The Effect of Frequency of Technology Uploads on Glycemic Control in Adult Insulin Pump Users

Contact Info

Product

Resources

About